Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

6 Jan 2021

Abstract excerpt

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33407700
DOI: 10.1186/s13045-020-01017-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationPMID 33407700Read ↗

Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.Semantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity Read ↗

Frontline treatment of AML in adults.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read ↗

Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Semantic proximity Read ↗

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read ↗

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsSemantic proximity Read ↗

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity Read ↗

Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.